Abstract 7182: EZH2 inhibition as a therapeutic strategy for castration resistant prostate cancer in combination with AR-antagonist enzalutamide
Shikhar Sharma(Pfizer (United States)), Pei‐Pei Kung(Pfizer (United States)), Sara B. Linker(Salk Institute for Biological Studies), Yong Zhang(Shanghai East Hospital), Thomas A. Paul(Pfizer (United States)), Colin A. Flaveny(Pfizer (United States)), Tao Xie(Foshan University), Kimberly H. Kim(Pfizer (United States)), Renea A. Taylor(The University of Melbourne), Sean Uryu(Pfizer (United States)), Whijae Roh(Broad Institute), Gail P. Risbridger(Discovery Institute), Xiaoli Wang(Wuhan University), Zhenxiong Wang(Pfizer (United States)), Jelena Petrovic(Cancer Research Institute), Robert A. Rollins(Pfizer (United States)), Conglin Fan(Pfizer (United States)), Joan Cao(Pfizer (United States)), Mitchell G. Lawrence(The University of Melbourne)
Cited by 0
Related Papers
Model-based Analysis of ChIP-Seq (MACS)
|Genome biology|2008|20k
Identifying ChIP-seq enrichment using MACS
|Nature Protocols|2012|2.1k
Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer
|Nature Genetics|2014|1.1k